Company logo

KYMR - Kymera Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Watertown, United States

KYMR price evolution
KYMR
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $158.41 $86.49 $54.69 $32.59
Short term investments $379.57 $274.2 $280.44 $265.2
Net receivables $0.86 $0.58
Inventory
Total current assets $543.73 $364.81 $340.79 $302.34
Long term investments $74.69 $45.3 $101.64 $162.53
Property, plant & equipment $21.72 $21.77 $20.5 $20.69
Goodwill & intangible assets
Total noncurrent assets $98.72 $69.58 $123.76 $184.84
Total investments $454.26 $319.51 $382.08 $427.73
Total assets $642.45 $434.39 $464.55 $487.18
Current liabilities
Accounts payable $5.03 $8.18 $8.35 $4.37
Deferred revenue $116.17 $134.94 $152.57 $170.39
Short long term debt $3.63 $3.46 $3.05 $3.26
Total current liabilities $94.49 $108.69 $110.14 $110.62
Long term debt $14.81 $14.84 $14.42 $14.73
Total noncurrent liabilities $64.83 $67.6 $79.17 $92.67
Total debt $18.44 $18.3 $17.47 $17.99
Total liabilities $159.32 $176.28 $189.31 $203.29
Shareholders' equity
Retained earnings -$195.08 -$166.5 -$141.84 -$128.76
Other shareholder equity -$0.15 -$0.01 -$0.13
Total shareholder equity $483.13 $258.1 $275.25 $283.89
(in millions $) 31 Dec 2020 31 Dec 2019
Current assets
Cash $32.59 $76.02
Short term investments $265.2 $15.94
Net receivables $0.58
Inventory
Total current assets $302.34 $92.84
Long term investments $162.53
Property, plant & equipment $20.69 $22.08
Goodwill & intangible assets
Total noncurrent assets $184.84 $23.86
Total investments $427.73 $15.94
Total assets $487.18 $116.7
Current liabilities
Accounts payable $4.37 $3.28
Deferred revenue $170.39 $52.99
Short long term debt $3.26 $3.38
Total current liabilities $110.62 $34.57
Long term debt $14.73 $17.82
Total noncurrent liabilities $92.67 $47.46
Total debt $17.99 $21.19
Total liabilities $203.29 $82.03
Shareholders' equity
Retained earnings -$128.76 -$76.46
Other shareholder equity -$0.13 $0.01
Total shareholder equity $283.89 -$74.41
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $34.03
Cost of revenue
Gross Profit $34.03
Operating activities
Research & development $38.31 $35.22 $25.96 $20.39
Selling, general & administrative $10.67 $8.03 $5.91 $5.17
Total operating expenses $48.97 $43.25 $31.87 $25.57
Operating income -$48.97 -$43.25 -$31.87 $8.47
Income from continuing operations
EBIT -$28.51 -$24.63 -$13.05 -$12.66
Income tax expense
Interest expense $0.07 $0.03 $0.02 $0.03
Net income
Net income -$28.58 -$24.66 -$13.07 -$12.69
Income (for common shares) -$28.58 -$24.66 -$13.07 -$12.69
(in millions $) 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $34.03 $2.93
Cost of revenue
Gross Profit $34.03 $2.93
Operating activities
Research & development $62.1 $37.16
Selling, general & administrative $18.23 $7.98
Total operating expenses $80.34 $45.14
Operating income -$46.3 -$42.2
Income from continuing operations
EBIT -$45.48 -$41.2
Income tax expense
Interest expense $0.12 $0.05
Net income
Net income -$45.59 -$41.25
Income (for common shares) -$45.59 -$41.25
(in millions $) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income -$28.58 -$24.66 -$13.07 -$12.69
Operating activities
Depreciation $0.67 $0.55 $0.48 $0.5
Business acquisitions & disposals
Stock-based compensation $7.4 $5.73 $3.17 $1.83
Total cash flows from operations -$37.26 -$30.51 -$22.82 -$20.07
Investing activities
Capital expenditures -$0.31 -$0.63 -$0.16 -$1.44
Investments -$136.56 $61.35 $44.49 -$2.55
Total cash flows from investing -$136.86 $60.72 $44.32 -$3.99
Financing activities
Dividends paid
Sale and purchase of stock $246.39 $1.78 $0.75 $0.42
Net borrowings -$0.35 -$0.19 -$0.15 -$0.15
Total cash flows from financing $246.04 $1.59 $0.59 $0.27
Effect of exchange rate
Change in cash and equivalents $71.92 $31.8 $22.09 -$23.79
(in millions $) 31 Dec 2020 31 Dec 2019
Net income -$45.59 -$41.25
Operating activities
Depreciation $1.76 $0.82
Business acquisitions & disposals
Stock-based compensation $5.19 $1.2
Total cash flows from operations $88.13 $17.91
Investing activities
Capital expenditures -$9.1 -$0.53
Investments -$413.49 -$15.95
Total cash flows from investing -$422.59 -$16.49
Financing activities
Dividends paid
Sale and purchase of stock $196.84 $0.07
Net borrowings -$0.55 -$0.37
Total cash flows from financing $289.26 $34.91
Effect of exchange rate
Change in cash and equivalents -$45.2 $36.33
Fundamentals
Market cap $2.04B
Enterprise value $1.90B
Shares outstanding 51.39M
Revenue $34.03M
EBITDA -$76.65M
EBIT -$78.85M
Net Income -$79.00M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -25.86
EV/Sales 55.92
EV/EBITDA -24.83
EV/EBIT -24.14
P/S ratio 60.03
P/B ratio 4.23
Book/Share 9.40
Cash/Share 3.08
EPS -$1.54
ROA -15.58%
ROE -24.30%
Debt/Equity 0.72
Net debt/EBITDA -0.01
Current ratio 5.75
Quick ratio 5.75